Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
Revenue$25.4 billion+5.9% YoY
EPS$0.09
Outlookraisedguidance
Collected automatically from companies' SEC filings (Form 8-K, Item 2.02)
Forensic equity research on US stocks. No spam, unsubscribe anytime.